ERRATA

The July 10, 2015, article by Bielack et al entitled “Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial,” (J Clin Oncol 33:2279-2287, 2015) contained errors.

In Figure 1, the dosing for both cisplatin and doxorubicin was given incorrectly. It was given as “120 g/m²” and “75 g/m²,” respectively, but should read as “120 mg/m²” and “75 mg/m².”

Also, in the Results section under the Treatment subheading, the target dosage for cisplatin was written as “240 mg/².” This should be “240 mg/m².”

The online version has been corrected in departure from the print. *Journal of Clinical Oncology* and the authors apologize for the errors.

DOI: 10.1200/JCO.2016.70.9923; published November 20, 2016

The May 20, 2016, article by van Hazel et al entitled “SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer,” (J Clin Oncol 34:1723-1731, 2016) contained an error.

Under Results, in the Efficacy section, under the “Site of first disease progression” subheading, the third sentence read as “There was a corresponding increase in first progression occurring outside the liver, particularly in the lung, for SIRT patients ($P < .001$), but there was no significant difference in timing of lung progression compared with control patients (median time to lung-only progression events, 8.9 v 12.5 months; $P = .049$ exploratory analysis).”

However, the words “control” and “SIRT” should be behind the appropriate numbers so the sentence reads as “There was a corresponding increase in first progression occurring outside the liver, particularly in the lung, for SIRT patients ($P < .001$), but there was no significant difference in timing of lung progression compared with control patients (median time to lung-only progression events, 8.9 [Control] v 12.5 [SIRT] months; $P = .049$ exploratory analysis).”

The online version has been corrected in departure from the print. The authors apologize for the mistake.

DOI: 10.1200/JCO.2016.70.8982; published November 20, 2016